Illinois Municipal Retirement Fund Has $824,000 Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Illinois Municipal Retirement Fund trimmed its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 7.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 64,563 shares of the biopharmaceutical company’s stock after selling 5,195 shares during the period. Illinois Municipal Retirement Fund’s holdings in Dynavax Technologies were worth $824,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Nisa Investment Advisors LLC boosted its stake in shares of Dynavax Technologies by 19.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 1,076 shares during the last quarter. Sanctuary Advisors LLC boosted its stake in shares of Dynavax Technologies by 6.3% during the 4th quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company’s stock worth $245,000 after buying an additional 1,109 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after buying an additional 1,457 shares during the last quarter. US Bancorp DE boosted its stake in shares of Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,034 shares during the last quarter. Finally, Parkman Healthcare Partners LLC boosted its stake in shares of Dynavax Technologies by 1.2% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 219,451 shares of the biopharmaceutical company’s stock worth $2,445,000 after buying an additional 2,629 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Trading Up 1.5 %

Shares of NASDAQ:DVAX opened at $13.79 on Monday. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $14.05. The company has a market capitalization of $1.71 billion, a P/E ratio of 76.61 and a beta of 1.32. The company has a 50-day simple moving average of $12.89 and a 200 day simple moving average of $12.12. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.05. The business had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. Sell-side analysts forecast that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on DVAX shares. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. HC Wainwright reiterated a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. The Goldman Sachs Group downgraded shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and cut their target price for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. Finally, William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.